AIIMS Bhopal IVF Facility Ready but Hits License Hurdle; Patients Wait

Bhopal’s first government IVF center at AIIMS is equipped with high-tech machinery and staff, but the lack of an operational license continues to delay affordable fertility treatments.

The long-standing wait for childless couples in Madhya Pradesh seeking affordable fertility treatment has hit another administrative roadblock. While the All India Institute of Medical Sciences (AIIMS) Bhopal has completed the setup of the state’s first government-run In-Vitro Fertilization (IVF) center, the facility remains non-functional as it awaits a mandatory operational license.

Despite the appointment of a specialized embryologist—the expert responsible for the delicate process of implanting embryos—and the installation of multi-crore equipment, the doors remain closed to the public. This delay comes nearly four years after the project was first announced in 2022, leaving thousands of hopeful parents in a state of limbo.

Administrative delays stall progress

The AIIMS management has confirmed that the application for the license has been submitted and is currently being processed. However, the timeline for the actual commencement of services remains vague. Sources within the hospital suggest that while the infrastructure is "battle-ready," the stringent norms of the Assisted Reproductive Technology (Regulation) Act mean that every procedural box must be checked before the first patient is admitted.

Huge cost relief expected

Currently, the demand for IVF in Madhya Pradesh is at an all-time high, with approximately 10,000 couples opting for the procedure annually at private clinics. These private cycles often cost between ₹1.5 lakh to ₹3 lakh, a price point that remains out of reach for many. Once the AIIMS Bhopal IVF facility becomes operational, the cost is expected to drop significantly to a range of ₹50,000 to ₹75,000, making it accessible to the lower and middle-income groups.

State-of-the-art medical infrastructure

The central government has allocated a budget of approximately ₹20 crore to ensure the center is at par with international standards. Beyond routine IVF, the facility is equipped to handle:

• Intracytoplasmic Sperm Injection (ICSI)

• Intrauterine Insemination (IUI)

• Embryo freezing and high-end incubation

• AI-based simulators for doctor training

The inclusion of a digital skill lab marks a first for the region, where doctors will use artificial intelligence to practice embryo transfers and hysteroscopy before performing them on patients.

Rising infertility in MP

The urgency for this center is underscored by a worrying trend in the state’s demographic health. Recent data from the Sample Registration System (SRS) indicates that the fertility rate in Madhya Pradesh has declined by 12.8% over the last decade. Health experts point toward changing lifestyles, delayed marriages, and rising cases of PCOS as primary factors driving the need for medical intervention.

Demographic shifts and outlook

Projections from the Ministry of Health and Family Welfare suggest a tightening window for the state’s reproductive health. While the youth population (ages 20-29) currently stands at over 1.5 crore, it is expected to shrink by 2047, while the elderly population will nearly triple. This shift emphasizes the importance of providing timely fertility support to the current generation of young couples.

Strict regulations in place

Medical professionals at AIIMS noted that IVF success is heavily dependent on age, urging couples not to delay treatment. Under current Indian laws, the age limit for IVF is capped at 50 for women and 55 for men. Furthermore, new regulations restrict the transfer of more than two embryos at a time to ensure the health of both the mother and the newborns.

As the file for the AIIMS Bhopal IVF facility license moves through government corridors, the hospital remains optimistic that the stalemate will end shortly, finally providing a state-sponsored lifeline to those dreaming of parenthood.

Ujjain Kashi SMA Type-1: Doctor Family Seeks ₹15 Crore Injection Aid

Five-month-old Kashi Dubey Puriya from Ujjain, daughter of a doctor couple, has been diagnosed with rare Spinal Muscular Atrophy (SMA) Type-1, mirroring the plight of Indore’s Anika. Her parents have appealed to Madhya Pradesh Chief Minister Dr Mohan Yadav for help to arrange the ₹15 crore gene therapy injection unavailable in India.

Symptoms Emerge Early

Kashi was born on November 14, 2025. Within weeks, her parents noticed she lacked normal movement in her limbs. Initial physiotherapy brought no relief, prompting the family to seek specialised care in Bhopal.

Diagnosis at AIIMS Bhopal

Doctors at AIIMS Bhopal clinically suspected SMA Type-1. Blood tests later confirmed the genetic disorder. The infant is now under the supervision of Dr Bhavna Digre, Head of the Medicine Department, where supportive medicines have been started.

Gene Therapy Only Option

Medical experts have indicated that gene therapy remains the sole effective treatment for SMA Type-1. Without it, the condition progressively weakens muscles and can become life-threatening. The family has been told that timely intervention is critical.

Injection Costs ₹15 Crore

The required Zolgensma injection must be imported from abroad. It costs around ₹15 crore and is not yet available in India. The doctor parents, already stretched financially, say the sum is beyond their reach.

Fundraiser Raises 30 Lakh

Dr Rohit Dubey Puriya, a senior resident in the Medicine Department at AIIMS Bhopal, and Dr Prakriti, a gynaecologist who has paused her work at Hamidia Hospital to care for her daughter, have launched an online fundraiser. A charity event also helped. So far, they have collected nearly ₹30 lakh.

Appeal to Chief Minister

The family has directly approached Chief Minister Dr Mohan Yadav for assistance. They have also urged social organisations, well-wishers and the public to step forward. Sources close to the family said every day counts as the baby’s condition could deteriorate rapidly.

Race Against Time

Grandparents have joined the appeal, describing sleepless nights watching their granddaughter’s struggle. The family stresses that SMA Type-1 leaves little margin for delay. They continue to explore every possible avenue while keeping treatment ongoing at AIIMS Bhopal.

This Ujjain Kashi SMA Type-1 case has once again drawn attention to the challenges families face in accessing advanced therapies for rare diseases in India. Public response and government support could make the difference between hope and despair for the infant.

All India Institute of Medical Sciences Bhopal has introduced a significant initiative aimed at identifying the scientific causes behind maternal deaths. The institute is now offering free pathological, or clinical, autopsies in cases of maternal mortality. This move is expected to play a crucial role in improving the maternal mortality rate in India by uncovering precise medical reasons behind such deaths.

A patient-friendly and dignified process

Unlike conventional postmortems, this clinical autopsy process is entirely non-invasive from a legal standpoint and does not involve police intervention. It is conducted solely based on the written consent of the deceased’s family. The objective is not legal investigation but medical understanding, making the process more respectful and less stressful for grieving families.

The procedure is carried out with utmost dignity. Specialists ensure that only minimal tissue samples required for examination are collected. All organs are carefully restored to their original position after the examination. No visible damage is caused to the face, and the body is respectfully handed back to the family after proper suturing.

Quick and efficient examination

According to the institute, the entire procedure is completed within approximately one and a half hours. Despite its short duration, the process is thorough and scientifically robust. Advanced diagnostic methods are used to ensure accurate findings, helping families gain clarity about the exact cause of death.

Importance of scientific investigation

The findings from histopathology and microbiology reports provide detailed insights into underlying medical conditions or complications that may not have been detected during routine clinical care. This information is vital not only for the family but also for the broader healthcare system.

Such data enables authorities to identify patterns and risk factors associated with maternal deaths. It helps determine which cases could have been prevented with timely intervention, thereby guiding improvements in maternal healthcare services.

Expert perspective on the initiative

Professor Dr. Madhavanand Kar, Executive Director of All India Institute of Medical Sciences Bhopal, emphasized that reducing maternal mortality remains a top priority. He noted that clinical autopsies allow medical experts to detect subtle and often overlooked causes of death. These insights can contribute to designing more effective strategies to prevent similar fatalities in the future.

A step toward better maternal healthcare

This initiative reflects a progressive shift in how maternal deaths are studied and addressed in India. By focusing on scientific evidence rather than procedural formalities, the program aims to bridge critical gaps in understanding maternal health risks. In the long run, it is expected to contribute to better policies, improved healthcare delivery, and ultimately, the saving of lives.

In a landmark development for public healthcare in Central India, AIIMS Bhopal is set to formally launch its lung transplant programme on March 28, 2026 — making it the first and only government hospital in the region to offer heart, kidney, bone marrow, and lung transplants all under one roof, and entirely free of cost.

This is not merely a medical milestone — it is a transformational moment for millions of patients across Madhya Pradesh, Chhattisgarh, and neighbouring states who have long been forced to travel to distant metro cities and pay lakhs at private hospitals for life-saving organ transplants.

What Makes This Launch So Significant?

With the regulatory site inspection now complete and final government approval imminent, AIIMS Bhopal is days away from becoming the only government hospital in Central India to offer heart, kidney, bone marrow, and lung transplants — all under one roof and entirely free of cost for eligible patients.

AIIMS Bhopal's entry into lung transplants is the next step in a transplant programme that has been steadily expanding since 2024. In January 2025, the institute performed Madhya Pradesh's first successful heart transplant — a landmark procedure that demonstrated its capacity to handle the most complex organ transplant operations. To date, AIIMS Bhopal has completed 3 heart transplants and 17 kidney transplants, building a strong foundation of transplant expertise.

The regulatory process is nearly complete. The inspection team has examined the infrastructure, operation theatres, ICU capacity, post-transplant care protocols, and the qualifications of the surgical team. Minor deficiencies identified during the inspection have since been addressed, and the institute now awaits the final official permission before performing its first lung transplant procedure.

A Broader Infrastructure Overhaul Underway

The lung transplant launch is only one piece of a much larger transformation at AIIMS Bhopal. The institute is set to install Gamma Knife and PET Scan machines, strengthen organ transplant services, and build a new dedicated ICU block. Robotic surgery facilities are also being expanded, enabling patients to receive cutting-edge treatments without leaving Madhya Pradesh.

A dedicated transplant operation theatre — separate from general surgical OTs and designed specifically for the sterile, infection-controlled environment that organ transplants demand — is being commissioned this year. This will allow heart, liver, kidney, and lung transplants to be performed under optimal conditions, with reduced waiting times and improved infection management.

India's Transplant Expansion: Other States Catching Up

AIIMS Bhopal is part of a national wave of organ transplant expansion across India's government hospitals. Several AIIMS campuses and state medical institutions — including in Odisha, Rajasthan, Uttar Pradesh, and Puducherry — have either recently launched or significantly expanded their liver and organ transplant programmes under central government guidance.

Teams from leading transplant institutions have trained surgeons and medical staff at multiple public sector hospitals across the country, helping start and restart liver transplant programmes that had previously been unavailable outside major private hospitals in Delhi, Mumbai, and Chennai.

Yet the numbers reveal how much ground remains to be covered. Lung transplants are currently limited to just 11 states across India, while heart transplants are available in only 14 states — indicating that these procedures are still largely restricted to states with the most advanced healthcare infrastructure.

What This Means for Patients

The impact of AIIMS Bhopal's expansion is deeply human. When the institute performs its first lung transplant, it will mean that one of medicine's most complex and life-giving procedures is within reach of a farmer from Vidisha, a coal miner from Korba, or a textile worker from Indore — all of them equally entitled to the chance at a second life that a lung transplant represents.

India's organ transplant demand far outpaces supply:

• An estimated 2 lakh patients die of liver failure or liver cancer annually in India, a significant portion of whom could be saved with a timely transplant.
• Around 50,000 people suffer from end-stage heart failure every year, yet only a small fraction ever receive transplants.
• Deceased organ donation rates in India remain critically low, making awareness and system-building more urgent than ever.

The Road Ahead: Free Treatment, Greater Access

AIIMS Bhopal's model — offering all major transplants free of charge at a government institution — sets a precedent that other AIIMS campuses and state medical colleges are now looking to replicate. With leading institutions in Delhi, Bhubaneswar, and now Bhopal active in the transplant space, the architecture of accessible organ transplantation in India is being rebuilt from the ground up.

Healthcare Policy Perspective: "The expansion of transplant services to government hospitals is not just a medical achievement — it is a social justice imperative. Every life-saving surgery available in a private hospital in Delhi or Mumbai must eventually be accessible to a patient in Bhopal or Bilaspur."

The AIIMS Bhopal lung transplant launch on March 28, 2026 is a defining chapter in India's public healthcare story. As organ transplant services expand across Central India and beyond — from liver units in eastern states to lung programmes in Madhya Pradesh — the promise of equitable, world-class medical care for every Indian is slowly, meaningfully becoming real. For patients who once had nowhere to turn, the doors of hope are finally opening.

In a story that blends elite sport, rare medicine, and a quiet public health crisis, the All India Institute of Medical Sciences (AIIMS), Bhopal has successfully performed a rare surgical procedure on an Asian Games athlete suffering from cryptorchidism — a condition medically known as "hidden testes" or undescended testes. It is a condition that affects millions of boys in India but is rarely discussed openly because of deep-rooted social stigma.

This AIIMS Bhopal hidden testes surgery is not just a medical milestone. It is a much-needed spotlight on a condition that, if left untreated, can lead to infertility, testicular cancer, and severe hormonal complications — yet remains largely undiagnosed and untreated across rural and semi-urban India.

What Is Cryptorchidism — The Condition That Hid in Plain Sight

Cryptorchidism literally means "hidden or obscure testis" and refers to an undescended or maldescended testis — one of the most common genital problems encountered in pediatric medicine.

In simple terms, during a baby boy's development inside the womb, the testes are formed inside the abdomen. They are supposed to travel from the abdomen, down through the groin, and into the scrotum during the third trimester. When they fail to complete this descent, the condition is called undescended testes.

At birth, approximately 3–5% of boys have undescended testes, and a large majority of these may descend naturally within the first 3 to 4 months of life. Outlook India However, when they do not, medical intervention becomes critical. The tragedy is that in India, many cases go undetected simply because parents are too embarrassed to raise the issue with a doctor.

The Asian Games Athlete — A Story of Hidden Pain and Hidden Courage

The young athlete operated on at AIIMS Bhopal had represented India at the Asian Games — competing at the highest continental level while unknowingly living with a medical condition that posed serious long-term health risks. His case was detected through routine medical examination, a reminder that even elite sports programmes in India still have critical gaps in comprehensive healthcare screening.

AIIMS Bhopal's Urology Department offers specialised treatment for congenital anomalies including undescended testes in both pediatric and adult patients, ensuring proper development and functionality. Bhopal Samachar The department, attended by over 45,000 patients annually including close to 8,400 new cases, and conducting more than 800 major surgeries each year, Bhopal Samachar is one of central India's most capable centres for exactly this kind of complex case.

The surgery — called orchiopexy — involves locating the undescended testicle and surgically repositioning it into the scrotum. The procedure is performed under general anesthesia and typically takes about 30 to 60 minutes. Most patients can expect a brief recovery period with mild discomfort or swelling in the surgical area.

Why Delayed Treatment Is Dangerous

What makes this case particularly significant is the athlete's age. Most experts strongly recommend surgery within the first year of life. Early recognition and surgical repair before one year of age remain the most important intervention to reduce the negative long-term impact of both unilateral and bilateral cryptorchidism.

When surgery is delayed — as it often is in India due to unawareness, poverty, or stigma — the consequences compound over time:

• Infertility risk: The warmer temperatures inside the body may impair the development of the testicles and affect the production of healthy sperm when the boy grows older.
• Cancer risk: Undescended testicles are at an increased risk for testicular cancer — studies show the risk is almost 35 times higher compared to the general population, typically occurring in the thirties.
• Torsion risk: Testicular torsion — where the blood vessels bringing blood to and from the testes get twisted — is another dangerous complication linked to undescended testes.

For a national-level athlete, the stakes are even higher. Hormonal balance, physical endurance, and reproductive health are all directly tied to testicular function. That this athlete continued competing at the Asian Games level despite the condition is both remarkable and concerning.

India's Silent Epidemic Nobody Talks About

Despite more than a century of research, many aspects of cryptorchidism remain controversial and not well defined — and untreated cryptorchidism clearly has deleterious effects on the testis over time.

In India, the problem is compounded by silence. Families in smaller towns and villages rarely seek urological evaluation for their children. Any abnormality related to sex organs arouses tremendous social and cultural issues, and it is imperative that children with this common problem receive the best and timely therapy.

The AIIMS Bhopal case, by becoming public, chips away at that wall of silence. When a celebrated athlete openly undergoes this procedure, it sends a powerful message to thousands of families across Madhya Pradesh and India: this is a treatable medical condition, not a source of shame.

What Parents and Families Must Do

Medical experts recommend the following steps:

• At birth: Check whether both testes are present in the scrotum. If either is missing, consult a pediatric urologist immediately
• By 6 months: If testes have not descended naturally, referral for surgical evaluation is essential
• Do not delay beyond 12–18 months: The main treatment for cryptorchidism is orchidopexy, and the widely accepted recommendation is that it should be performed between 6 and 12 months of age, but not beyond 18 months TheQuint
• For adults with undiagnosed cases: AIIMS Bhopal and other major hospitals offer evaluation and surgical treatment — it is never entirely too late to seek help

Opinion: Sport Gave a Young Man His Diagnosis — Now Let It Give Others Awareness

There is an irony in the story of this Asian Games athlete. His remarkable physical achievements — the discipline, the training, the competition — likely contributed to the medical screening that finally identified his condition. Most Indian boys with cryptorchidism will never receive that screening.

India's sports infrastructure, still growing, must integrate comprehensive medical screening as a non-negotiable standard. And India's public health conversation must make space for conditions like cryptorchidism — stripping away the stigma so that families feel comfortable seeking early intervention.

AIIMS Bhopal performed a surgery. But the real operation needed in India is on awareness.